MHC loci affecting cervical cancer risk: Distinguishing the effects of HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2

Genes and Immunity

Volumn 9, Issue 7, 2008, Pages 613-623

  Ivansson, E L ^a   Magnusson, J J ^a   Magnusson, P K E ^b   Erlich, H A ^c   Gyllensten, U B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQB1 ANTIGEN; LYMPHOTOXIN; MEMBRANE PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ADULT; ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DQ ANTIGENS; HUMANS; LINKAGE DISEQUILIBRIUM; LYMPHOTOXIN-ALPHA; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 67651149672     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2008.58     Document Type: Article

References (60)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999; 400: 29-30.
4. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet 2004; 13: 1951-1958.
5. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: A review. Virus Res 2002; 89: 229-240.
6. Sanjeevi CB, Hjelmstrom P, Hallmans G, Wiklund F, Lenner P, Angstrom T et al. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996; 68: 409-414.
7. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001; 93: 817-822.
8. Ghaderi M, Wallin KL, Wiklund F, Zake LN, Hallmans G, Lenner P et al Risk of invasive cervical cancer associated with polymorphic HLA DR/DQ haplotypes. Int J Cancer 2002; 100: 698-701.
9. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factoralpha as a tumour promoter. Eur J Cancer 2006; 42: 745-750.
10. Tjiong MY, van der Vange N, ter Schegget JS, Burger MP, ten Kate FW, Out TA. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine 2001; 14: 357-360.
11. Azar KK, Tani M, Yasuda H, Sakai A, Inoue M, Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol 2004; 35 1376-1384.
12. Gaiotti D, Chung J, Iglesias M, Nees M, Baker PD, Evans CH et al. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a rasdependent pathway. Mol Carcinog 2000; 27 97-109.
13. Kyo S, Inoue M, Hayasaka N, Inoue T, Yutsudo M, Tanizawa O et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology 1994; 200: 130-139.
14. Vieira KB, Goldstein DJ, Villa LL. Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirusimmortalized human keratinocytes. Cancer Res 1996; 56: 2452-2457.
15. Woodworth CD, McMullin E, Iglesias M, Plowman GD. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci USA 1995; 92: 2840-2844.
16. Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem 2002; 48: 1218-1224.
17. Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL et al TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 2005; 191: 969-976.
18. Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A et al. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 2005; 334 588-592.
19. Ghaderi M, Nikitina L, Peacock CS, Hjelmstrom P, Hallmans G, Wiklund F et al. Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev 2000; 9: 1067-1070.
20. Ghaderi M, Nikitina Zake L, Wallin K, Wiklund F, Hallmans G, Lenner P et al. Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. Hum Immunol 2001; 62: 1153-1158.
21. Gostout BS, Poland GA, Calhoun ES, Sohni YR, Giuntoli II RL, McGovern RM et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 2003; 88: 326-332.
22. Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer 2006; 6: 24.
23. Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 2001; 166: 41-46.
24. Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNFalpha polymorphism frequencies in HPVassociated cervical dysplasia. Gynecol Oncol 2004; 92: 675-679.
25. Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the position of the tumor -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer 2003; 13: 148-153.
26. Niwa Y, Hirose K, Matsuo K, Tajima K, Ikoma Y, Nakanishi T et al. Lymphotoxin-alpha polymorphism and the risk of cervical cancer in Japanese subjects. Cancer Lett 2005; 218: 63-68.
27. Jackson DG, Capra JD. TAP2 association with insulindependent diabetes mellitus is secondary to HLA-DQB1. Hum Immunol 1995; 43: 57-65.
28. Powis SH, Tonks S, Mockridge I, Kelly AP, Bodmer JG, Trowsdale J. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 1993; 37: 373-380.
29. McCluskey J, Rossjohn J, Purcell AW. TAP genes and immunity. Curr Opin Immunol 2004; 16: 651-659.
30. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL et al Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179: 335-340.
31. Fowler NL, Frazer IH. Mutations in TAP genes are common in cervical carcinomas. Gynecol Oncol 2004; 92: 914-921.
32. Deshpande A, Wheeler CM, Hunt WC, Peyton CL, White PS, Valdez YE et al. Variation in HLA class I antigen-processing genes and susceptibility to human papillomavirus type 16-associated cervical cancer. J Infect Dis 2008; 197: 371-381.
33. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK et al. Gene map of the extended human MHC. Nat Rev Genet 2004; 5: 889-899.
34. Miretti MM, Walsh EC, Ke X, Delgado M, Griffiths M, Hunt S et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005; 76: 634-646.
35. Cuzick J, Terry G, Ho L, Monaghan J, Lopes A, Clarkson P et al. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer 2000; 82: 1348-1352.
36. Gregoire L, Lawrence WD, Kukuruga D, Eisenbrey AB, Lancaster WD. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int J Cancer 1994; 57: 504-507.
37. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 1996; 67 595-602.
38. Zoodsma M, Nolte IM, Te Meerman GJ, De Vries EG, Van der Zee AG. HLA genes and other candidate genes involved in susceptibility for (pre)neoplastic cervical disease. Int J Oncol 2005; 26: 769-784.
39. Dao DD, Sierra-Torres CH, Robazetti SC, de Gomez MN, Konig R, Lema C et al. HLA-DQB1 and cervical cancer in Venezuelan women. Gynecol Oncol 2005; 96: 349-354.
40. Montoya L, Saiz I, Rey G, Vela F, Clerici-Larradet N. Cervical carcinoma: Human papillomavirus infection and HLAassociated risk factors in the Spanish population. Eur J Immunogenet 1998; 25: 329-337.
41. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Association between HLA DQB1* 03 and cervical intra-epithelial neoplasia. Mol Med 1995; 1: 161-171.
42. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ et al. IMGT/HLA and IMGT/MHC: Sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 2003; 31 311-314.
43. Ettinger RA, Papadopoulos GK, Moustakas AK, Nepom GT, Kwok WW. Allelic variation in key peptide-binding pockets discriminates between closely related diabetes-protective and diabetes-susceptible HLA-DQB1*06 alleles. J Immunol 2006; 176: 1988-1998.
44. Siebold C, Hansen BE, Wyer JR, Harlos K, Esnouf RE, Svejgaard A et al Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA 2004; 101: 1999-2004.
45. Erlich HA, Griffith RL, Bugawan TL, Ziegler R, Alper C, Eisenbarth G. Implication of specific DQB1 alleles in genetic susceptibility and resistance by identification of IDDM siblings with novel HLA-DQB1 allele and unusual DR2 and DR1 haplotypes. Diabetes 1991; 40: 478-481.
46. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8: 1398-1404.
47. Powis SJ, Deverson EV, Coadwell WJ, Ciruela A, Huskisson NS, Smith H et al. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I moleculed. Nature 1992; 357: 211-215.
48. Daniel S, Caillat-Zucman S, Hammer J, Bach JF, van Endert PM. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. J Immunol 1997; 159: 2350-2357.
49. Carrington M, Colonna M, Spies T, Stephens JC, Mann DL. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics 1993; 37: 266-273.
50. Cullen M, Noble J, Erlich H, Thorpe K, Beck S, Klitz W et al. Characterization of recombination in the HLA class II region. Am J Hum Genet 1997; 60: 397-407.
51. Cullen M, Erlich H, Klitz W, Carrington M. Molecular mapping of a recombination hotspot located in the second intron of the human TAP2 locus. Am J Hum Genet 1995; 56: 1350-1358.
52. Caillat-Zucman S, Daniel S, Djilali-Saiah I, Timsit J, Garchon HJ, Boitard C et al. Family study of linkage disequilibrium between TAP2 transporter and HLA class II genes. Absence of TAP2 contribution to association with insulin-dependent diabetes mellitus. Hum Immunol 1995; 44: 80-87.
53. Zhang SL, Chabod J, Penfornis A, Reviron D, Tiberghien P, Wendling D et al. TAP1 and TAP2 gene polymorphism in rheumatoid arthritis in a population in eastern France. Eur J Immunogenet 2002; 29: 241-249.
54. Noble JA, Valdes AM, Lane JA, Green AE, Erlich HA. Linkage disequilibrium with predisposing DR3 haplotypes accounts for apparent effects of tumor necrosis factor and lymphotoxin-alpha polymorphisms on type 1 diabetes susceptibility. Hum Immunol 2006; 67: 999-1004.
55. Barcellos LF, Begovich AB, Reynolds RL, Caillier SJ, Brassat D, Schmidt S et al. Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. Ann Neurol 2004; 55: 793-800.
56. Bugawan TL, Erlich HA. Rapid typing of HLA-DQB1 DNA polymorphism using nonradioactive oligonucleotide probes and amplified DNA. Immunogenetics 1991; 33: 163-170.
57. Allen-Brady K, Wong J, Camp NJ. PedGenie: An analysis approach for genetic association testing in extended pedigrees and genealogies of arbitrary size. BMC Bioinformatics 2006; 7: 209.
58. Curtin K, Wong J, Allen-Brady K, Camp NJ. PedGenie: Meta genetic association testing in mixed family and case-control designs. BMC Bioinformatics 2007; 8: 448.
59. Barrett JC, Fry B, Maller J, Daly MJ. HaploView: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
60. Gaunt TR, Rodriguez S, Zapata C, Day IN. MIDAS: Software for analysis and visualisation of interallefic disequilibrium between multiallelic markers. BMC Bioinformatics 2006; 7: 227.